617 related articles for article (PubMed ID: 33277913)
1. Immunosuppression management in renal transplant recipients with normal-immunological risk: 10-year results from the Swiss Transplant Cohort Study.
Krisl A; Stampf S; Hauri D; Binet I; Mueller T; Sidler D; Hadaya K; Golshayan D; Pascual M; Koller M; Dickenmann M; The Swiss Transplant Cohort Study Stcs
Swiss Med Wkly; 2020 Nov; 150():w20354. PubMed ID: 33277913
[TBL] [Abstract][Full Text] [Related]
2. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
3. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO
Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
[TBL] [Abstract][Full Text] [Related]
4. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
5. Effect of once-per-day tacrolimus versus twice-per-day ciclosporin on 3-year incidence of chronic lung allograft dysfunction after lung transplantation in Scandinavia (ScanCLAD): a multicentre randomised controlled trial.
Dellgren G; Lund TK; Raivio P; Leuckfeld I; Svahn J; Holmberg EC; Olsen PS; Halme M; Fiane A; Lindstedt S; Riise GC; Magnusson J
Lancet Respir Med; 2024 Jan; 12(1):34-44. PubMed ID: 37703908
[TBL] [Abstract][Full Text] [Related]
6. A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children.
Yao G; Albon E; Adi Y; Milford D; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2006 Dec; 10(49):iii-iv, ix-xi, 1-157. PubMed ID: 17134597
[TBL] [Abstract][Full Text] [Related]
7. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
[TBL] [Abstract][Full Text] [Related]
8. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
Ulsh PJ; Yang HC; Holman MJ; Ahsan N
J Transpl Coord; 1999 Jun; 9(2):114-8. PubMed ID: 10703393
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus: a further update of its use in the management of organ transplantation.
Scott LJ; McKeage K; Keam SJ; Plosker GL
Drugs; 2003; 63(12):1247-97. PubMed ID: 12790696
[TBL] [Abstract][Full Text] [Related]
10. Decreased incidence of acute rejection in adolescent kidney transplant recipients using antithymocyte induction and triple immunosuppression.
Schwartz JJ; Ishitani MB; Weckwerth J; Morgenstern B; Milliner D; Stegall MD
Transplantation; 2007 Sep; 84(6):715-21. PubMed ID: 17893604
[TBL] [Abstract][Full Text] [Related]
11. Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression.
Chakrabarti P; Wong HY; Scantlebury VP; Jordan ML; Vivas C; Ellis D; Lombardozzi-Lane S; Hakala TR; Fung JJ; Simmons RL; Starzl TE; Shapiro R
Transplantation; 2000 Sep; 70(5):760-4. PubMed ID: 11003353
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
13. Long-term, prolonged-release tacrolimus-based immunosuppression in de novo kidney transplant recipients: 5-year prospective follow-up of the ADHERE study patients.
Rummo O; Carmellini M; Kamar N; Durrbach A; Mousson C; Caputo F; Mathe Z; Christiaans MHL; Kuypers DRJ; Klempnauer J; Anaokar S; Hurst M; Kazeem G; Undre N; Lehner F
Transpl Int; 2020 Feb; 33(2):161-173. PubMed ID: 31536654
[TBL] [Abstract][Full Text] [Related]
14. Treatment strategies to minimize or prevent chronic allograft dysfunction in pediatric renal transplant recipients: an overview.
Höcker B; Tönshoff B
Paediatr Drugs; 2009; 11(6):381-96. PubMed ID: 19877724
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients.
de Boer SE; Sanders JSF; Bemelman FJ; Betjes MGH; Burgerhof JGM; Hilbrands L; Kuypers D; van Munster BC; Nurmohamed SA; de Vries APJ; van Zuilen AD; Hesselink DA; Berger SP
BMC Nephrol; 2021 Jun; 22(1):208. PubMed ID: 34078323
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial.
Zuckermann A; Reichenspurner H; Birsan T; Treede H; Deviatko E; Reichart B; Klepetko W
J Thorac Cardiovasc Surg; 2003 Apr; 125(4):891-900. PubMed ID: 12698153
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of Tacrolimus without Basiliximab in Well-Matched Living-Donor Renal Transplant Recipients in Korea.
Baek CH; Kim JH; Yu H; Shin E; Cho H; Kim H; Yang WS; Han DJ; Park SK
Exp Clin Transplant; 2016 Aug; 14(4):389-93. PubMed ID: 27228054
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data.
Webster AC; Woodroffe RC; Taylor RS; Chapman JR; Craig JC
BMJ; 2005 Oct; 331(7520):810. PubMed ID: 16157605
[TBL] [Abstract][Full Text] [Related]
19. Open prospective study to evaluate cardiovascular risk factors and renal function in 2 dosage regimens of tacrolimus combined with mycophenolate mofetil and steroids in renal transplant patients: 5-year results.
Chamienia A; Dębska-Ślizień A; Król E; Biedunkiewicz B; Rutkowski B
Transplant Proc; 2014 Oct; 46(8):2714-8. PubMed ID: 25380901
[TBL] [Abstract][Full Text] [Related]
20. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]